Vanda Pharmaceuticals’ Price Target Raised 21% to $17 from $14
Analyst firm B. Riley lifted Vanda Pharmaceuticals’ price target by 21%, from $14 to $17. The move reflects an upward revision of valuation assumptions that increases the stock’s projected upside potential.
1. Price Target Increase
B. Riley raised its price target for Vanda Pharmaceuticals by 21%, lifting it to $17 from $14. This revision updates the stock’s valuation benchmark and signals higher analyst expectations for the company’s future performance.
Related News
TQQQ
ProShares 3x Nasdaq-100 ETF Gathers $31.3B, Hits 38.6% YTD Gain
TQQQ•
JPM
J.P. Morgan Joins SpaceX $1.75 Trillion Nasdaq IPO With $1.45B Bitcoin Disclosure
JPM•
ALSN
Allison Transmission Wins Penske Best Supplier Award and Highlights Next-Gen 9-Speed
ALSN•
CNS
Cohen & Steers Partners with J.P. Morgan on Short-Duration Hybrid Credit Fund Expansion
CNS•
GOOGL
Google and Blackstone Form $5B AI Cloud JV for 500MW Capacity by 2027
GOOGL•
Sources
F